The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
- 1 May 2008
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (9), 2519-2526
- https://doi.org/10.1158/1078-0432.ccr-07-2223
Abstract
The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of hematopoietic cells. These cells are supported by fibroblast-like bone marrow stromal cells, osteoblasts, and osteoclasts which secrete soluble factors and extracellular matrix proteins that mediate these functions. This rich environment serves as a safe haven not only for normal and malignant hematopoietic cells, but also for epithelial tumor cells that metastasize to bone, offering protection from chemotherapeutic agents by common mechanisms. Soluble factors produced in the bone marrow, such as stromal cell–derived factor-1 and interleukin-6, mediate homing, survival, and proliferation of tumor cells, and integrin-mediated adhesion sequesters tumor cells to this protective niche. Environment-mediated drug resistance includes a combination of soluble factors and adhesion, and can be subdivided into soluble factor–mediated drug resistance and cell adhesion–mediated drug resistance. Because it is induced immediately by the microenvironment and is independent of epigenetic or genetic changes caused by the selective pressure of drug exposure, environment-mediated drug resistance is a form of de novo drug resistance. In this form of drug resistance, tumor cells are transiently and reversibly protected from apoptosis induced by both chemotherapy and physiologic mediators of cell death. This protection allows tumor cells to survive the insult of chemotherapy, leading to minimal residual disease, and thereby increases the probability for the development of acquired drug resistance.Keywords
This publication has 72 references indexed in Scilit:
- Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomasBlood, 2007
- Prostate cancer specific integrin αvβ3 modulates bone metastatic growth and tissue remodelingOncogene, 2007
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006
- Integrin ligands at a glanceJournal of Cell Science, 2006
- A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor developmentThe Journal of Experimental Medicine, 2006
- A small molecule, orally active, α4β1/α4β7 dual antagonist reduces leukocyte infiltration and airway hyper‐responsiveness in an experimental model of allergic asthma in Brown Norway ratsBritish Journal of Pharmacology, 2006
- ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinaseCell Death & Differentiation, 2006
- Integrin signalling during tumour progressionNature Reviews Molecular Cell Biology, 2004
- Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor inductionCancer Cell, 2004
- Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cellsOncogene, 2001